IL-AIT-WORLDWIDE
28.8.2024 17:04:29 CEST | Business Wire | Press release
Global supply chain solutions leader, AIT Worldwide Logistics, is pleased to announce the launch of its new artificial intelligence (AI) and data science team, a corporate-level department created to amplify the organization’s investment in data. The team will set the stage for the future implementation of next-generation AI tools to further enhance the company’s robust customer interface. To lead the new group, AIT’s Patrick Chew has been appointed to vice president, AI and data science.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828389373/en/
Data is an integral pillar at AIT, with the new AI and data science team working to enable a new era of dramatic growth for the company. (Photo: Business Wire)
“AIT is continually looking towards the future,” said Chairman and Chief Executive Officer, Vaughn Moore. “With the establishment of the AI and data science team, the company is prepared to capitalize on generative AI, natural language processing, machine learning, large language models, and other advancing technologies.”
Over the course of 25 years, Chew has helped numerous Fortune 500 companies improve their business intelligence, analytics, and data enablement. He most recently served as the head of Caterpillar’s enterprise data governance office. Since joining the company in January 2024, Chew has been responsible for directing data enablement efforts. He reports to AIT’s President and Chief Operating Officer, Keith Tholan.
“AIT leadership has made a significant commitment to transform our data, and we are delighted to have Patrick in a role where he can leverage his vast experience to guide our ongoing data journey for the primary benefit of our customers and teammates,” Tholan said.
“Data is a common denominator that informs and impacts every aspect of the business,” he added. “And at AIT, our investment in taking data enablement to the next level clearly signals that data is an integral pillar of the organization, with the new AI and data science team working to enable a new era of dramatic growth for the company.”
The AI and data science group is comprised of three key teams:
- Data enablement – leading a disciplined, firmwide process to reorganize existing data strongholds into next-gen-compatible assets that will build new levels of trust with stakeholders through increased efficiency and ever-improving solutions
- AI governance and data science – developing new AI business features with an emphasis on heightened accuracy and privacy protections for customers and teammates as the technology continues to mature and evolve
- Business intelligence and analytics – providing dedicated, centralized reporting and visualization needs across the organization
The AI and data science team is implementing a regimented approach to transform data across AIT’s global network, including steps to redefine core domains and enhance time-tested workflows. Data management based on a newly configured single version of truth will be well-positioned to support powerful new key performance indicators.
“Treating data as an asset involves rigorous efforts to reorganize and harness millions of inputs, which will be applied in meaningful ways to enhance business intelligence, boost efficiency and spur innovation,” Chew said.
“Ambitiously raising the bar to loftier heights for data quality and governance ultimately improves outcomes for stakeholders as we continue to earn our customers’ trust,” he added. “Our AI and data science initiative will further differentiate AIT with shippers and investors when compared to others in the freight forwarding industry.”
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, energy, food, government, high-tech, industrial, life sciences and marine. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes end-to-end deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 150 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828389373/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom